Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Natalia Reoutova, 19 Nov 2019

A 70-month prospective study in Southern Chinese women, sponsored by the World Cancer Research Fund, finds no evidence of pre-diagnosis soy intake negatively affecting mortality or recurrence among breast cancer survivors. On the contrary, the results indicate that moderate soy intake may be associated with better outcomes.

Gout not a risk factor for colorectal cancer

08 Nov 2019

Individuals with and without gout appear to have a similar risk of developing colorectal cancer, suggesting that gout does not contribute to a risk increase, a study has found.

Researchers used data from the Taiwan National Health Insurance Research Database, identifying 28,061 gout patients (mean age, 53.4 years) and 84,248 matched controls (mean age, 51.1 years) without the medical condition.

Compared with controls, gout patients were more likely to have comorbidities, including hypertension (48.4 percent vs 24.2 percent; p<0.0001), diabetes mellitus (22.4 percent vs 12.3 percent; p<0.0001) and hyperlipidaemia (35.0 percent vs 14.7 percent; p<0.0001).

Over 13 years of follow-up, colorectal cancer occurred with greater frequency in the gout cohort. The incidence rate per 1,000 person-years was 2.44 as compared with 2.13 in the control cohort (incidence rate ratio, 1.15, 95 percent confidence interval [CI], 1.04–1.26). 

However, in a Cox proportional hazards model adjusted for age, gender, urbanization status and comorbidities, gout was not significantly associated with increased risk of incident colorectal cancer (adjusted hazard ratio [HR], 1.03, 95 percent CI, 0.93–1.14).

The researchers additionally conducted a posterior analysis comparing colorectal cancer risk between gout patients with and without prescriptions for allopurinol. Results indicated a weak inverse association between allopurinol and the cancer risk (HR, 0.95, 95 percent CI, 0.80–1.12), although the analysis was not controlled for risk factors for colorectal cancer.

Therefore, additional pharmaco-epidemiological studies are needed to establish whether allopurinol plays a role in preventing the development of colorectal cancer in patients with gout, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Natalia Reoutova, 19 Nov 2019

A 70-month prospective study in Southern Chinese women, sponsored by the World Cancer Research Fund, finds no evidence of pre-diagnosis soy intake negatively affecting mortality or recurrence among breast cancer survivors. On the contrary, the results indicate that moderate soy intake may be associated with better outcomes.